CPT1A and neoplasm: The combination of osimertinib and sitagliptin resulted in a greater reduction in GPF‐positive tumor cells and a concurrent decrease in DPP4, Nrf2, and CPT1A expression (Figure 7C; Figure S16A–C, Supporting Information).